Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Heron Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1983-01-01

Employees: 126

Market Cap: $292.7M

Website: http://www.herontx.com

Clinical Trials

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.

Phase 4

Completed

Conditions: Total Shoulder Arthroplasty
Multimodal Analgesia
Postoperative Pain

Interventions: Drug: HTX-011
Drug: Bupivacaine Hydrochloride
Drug: Ibuprofen
Drug: Acetaminophen
Device: Luer lock applicator

First Posted Date: 2023-10-31

Last Posted Date: 2023-10-31

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 30

Registration Number: NCT06109415

Locations: 🇺🇸
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸
Center for Orthopaedic Reconstruction and Excellence, Jenks, Oklahoma, United States
🇺🇸
First Surgical Hospital, Bellaire, Texas, United States

and more 2 locations

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE

Phase 4

Completed

Conditions: Analgesia

Interventions: Drug: HTX-011
Drug: Bupivacaine Hydrochloride
Drug: Ibuprofen
Drug: Acetaminophen
Device: Luer lock applicator

First Posted Date: 2023-10-31

Last Posted Date: 2023-10-31

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 30

Registration Number: NCT06109428

Locations: 🇺🇸
First Surgical Hospital, Bellaire, Texas, United States
🇺🇸
Endeavor Clinical Trials, LLC, San Antonio, Texas, United States

Safety Study of Repeat Doses of SUSTOL in Adults

Phase 4

Active, not recruiting

Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions: Drug: SUSTOL

First Posted Date: 2022-06-28

Last Posted Date: 2023-07-28

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 300

Registration Number: NCT05434663

Locations: 🇺🇸
Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

Phase 4

Active, not recruiting

Conditions: Analgesia

Interventions: Drug: HTX-011
Drug: Bupivacaine Hydrochloride
Device: Luer lock applicator
Drug: Ibuprofen
Drug: Acetaminophen

First Posted Date: 2021-11-05

Last Posted Date: 2023-10-26

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 90

Registration Number: NCT05109312

Locations: 🇺🇸
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸
Gulfcoast Research Institute, Sarasota, Florida, United States
🇺🇸
The Orthopaedic Center, Tulsa, Oklahoma, United States

and more 4 locations

HTX-011 in Spinal Surgery

Phase 2

Completed

Conditions: Post-Operative Pain
Lumbar Laminectomy

Interventions: Drug: Bupivacaine HCI without epinephrine
Drug: HTX-011
Device: Luer Lock Applicator

First Posted Date: 2021-06-02

Last Posted Date: 2023-06-12

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 32

Registration Number: NCT04911062

Locations: 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸
Lotus Clinical Research, LLC, Pasadena, California, United States
🇺🇸
Kansas Spine and Specialty Hospital, Wichita, Kansas, United States

and more 9 locations

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Aprepitant injectable emulsion
Drug: Saline Placebo

First Posted Date: 2020-07-14

Last Posted Date: 2022-08-30

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 27

Registration Number: NCT04470622

Locations: 🇺🇸
Helen Keller Hospital, Sheffield, Alabama, United States
🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Dose-Escalation Study of HTX-034 Following Bunionectomy

Phase 1

Completed

Conditions: Bunions

Interventions: Drug: HTX-034
Drug: Bupivacaine HCl
Device: Luer lock applicator

First Posted Date: 2020-05-21

Last Posted Date: 2022-02-15

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 73

Registration Number: NCT04398329

Locations: 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸
First Surgical Hospital, Bellaire, Texas, United States
🇺🇸
Endeavor Clinical Trials, LLC, San Antonio, Texas, United States

and more 1 locations

Extended Delivery of Bupivacaine Study in Herniorrhaphy

Phase 4

Completed

Conditions: Analgesia

Interventions: Drug: Bupivacaine liposome injectable suspension
Drug: Bupivacaine HCl without epinephrine via continuous infusion

First Posted Date: 2019-09-25

Last Posted Date: 2019-09-26

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 32

Registration Number: NCT04102267

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

Phase 3

Completed

Conditions: Analgesia

Interventions: Drug: HTX-011
Drug: Ibuprofen
Drug: Acetaminophen
Drug: +/- Bupivacaine HCl
Drug: Celecoxib
Device: Luer Lock Applicator

First Posted Date: 2019-06-05

Last Posted Date: 2023-08-31

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 116

Registration Number: NCT03974932

Locations: 🇺🇸
Helen Keller Hospital, Sheffield, Alabama, United States
🇺🇸
Phoenix Clinical Research, LLC, Tamarac, Florida, United States
🇺🇸
Midwest Clinical Research Center, LLC, Dayton, Ohio, United States

and more 3 locations

HTX-011 Administration Study in Planned Caesarean Section Procedure

Phase 2

Completed

Conditions: Analgesia

Interventions: Drug: HTX-011
Device: Luer Lock Applicator
Drug: Ibuprofen
Drug: Acetaminophen

First Posted Date: 2019-05-20

Last Posted Date: 2022-03-14

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 25

Registration Number: NCT03955211

Locations: 🇺🇸
Helen Keller Hospital, Sheffield, Alabama, United States
🇺🇸
Sharp Mary Birch Hospital for Women and Newborns, San Diego, California, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy